Checkpoint kinase inhibitors - Pipeline Insight, 2022
This report can be delivered to the clients within 48 hours
DelveInsight’s, “Checkpoint kinase inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Checkpoint kinase inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Checkpoint kinase inhibitors: Overview
Checkpoint kinases (Chks) are protein kinases that are involved in cell cycle control. The checkpoint kinases, Chk1 and Chk2 are Ser/Thr protein kinases, which function as key regulatory kinases in cellular DNA damage response pathways limiting cell-cycle progression in the presence of DNA damage. Cells that suffer DNA damage activate the checkpoint kinases CHK1 and CHK2, which signal to initiate repair processes, limit cell-cycle progression and prevent cell replication, until the damaged DNA is repaired. The development of checkpoint kinase inhibitors for the treatment of cancer has been a major objective in drug discovery. Checkpoint kinase 1 (CHK1) is an oncology target of significant current interest. Inhibition of CHK1 abrogates DNA damage-induced cell cycle checkpoints and sensitizes p53 deficient cancer cells to genotoxic therapies. The majority of CHK1 inhibitors are ATP competitive and bind directly to the hinge peptide region found between the N- and C-terminal lobes of the kinase domain. Checkpoint kinase inhibitors offer the promise of enhancing the effectiveness of widely prescribed cancer chemotherapies and radiotherapy by inhibiting the DNA damage response, as well as the potential for single agent efficacy. Due to their potential application as novel anticancer therapies, inhibitors of CHK1 and CHK2 have become the focus of numerous drug discovery projects.
Report Highlights
This segment of the Checkpoint kinase inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Checkpoint kinase inhibitors Emerging Drugs
Further product details are provided in the report……..
Checkpoint kinase inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different Checkpoint kinase inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
Checkpoint kinase inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Checkpoint kinase inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Checkpoint kinase inhibitors drugs.
Checkpoint kinase inhibitors Report Insights
Current Scenario and Emerging Therapies:
DelveInsight’s, “Checkpoint kinase inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Checkpoint kinase inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Checkpoint kinase inhibitors: Overview
Checkpoint kinases (Chks) are protein kinases that are involved in cell cycle control. The checkpoint kinases, Chk1 and Chk2 are Ser/Thr protein kinases, which function as key regulatory kinases in cellular DNA damage response pathways limiting cell-cycle progression in the presence of DNA damage. Cells that suffer DNA damage activate the checkpoint kinases CHK1 and CHK2, which signal to initiate repair processes, limit cell-cycle progression and prevent cell replication, until the damaged DNA is repaired. The development of checkpoint kinase inhibitors for the treatment of cancer has been a major objective in drug discovery. Checkpoint kinase 1 (CHK1) is an oncology target of significant current interest. Inhibition of CHK1 abrogates DNA damage-induced cell cycle checkpoints and sensitizes p53 deficient cancer cells to genotoxic therapies. The majority of CHK1 inhibitors are ATP competitive and bind directly to the hinge peptide region found between the N- and C-terminal lobes of the kinase domain. Checkpoint kinase inhibitors offer the promise of enhancing the effectiveness of widely prescribed cancer chemotherapies and radiotherapy by inhibiting the DNA damage response, as well as the potential for single agent efficacy. Due to their potential application as novel anticancer therapies, inhibitors of CHK1 and CHK2 have become the focus of numerous drug discovery projects.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Checkpoint kinase inhibitors R&D. The therapies under development are focused on novel approaches for Checkpoint kinase inhibitors.
This segment of the Checkpoint kinase inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Checkpoint kinase inhibitors Emerging Drugs
- BI 765063: Boehringer Ingelheim
- CBP501: CanBas
Further product details are provided in the report……..
Checkpoint kinase inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different Checkpoint kinase inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on Checkpoint kinase inhibitors
- Phases
- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical
- Molecule Type
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
Checkpoint kinase inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Checkpoint kinase inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Checkpoint kinase inhibitors drugs.
Checkpoint kinase inhibitors Report Insights
- Checkpoint kinase inhibitors Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing Checkpoint kinase inhibitors drugs?
- How many Checkpoint kinase inhibitors drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for Checkpoint kinase inhibitors?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Checkpoint kinase inhibitors therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Checkpoint kinase inhibitors and their status?
- What are the key designations that have been granted to the emerging drugs?
- Boehringer Ingelheim
- CanBas
- Vernalis
- Sierra Oncology
- Pharos I&BT Co
- Array BioPharma
- Eli Lilly and Company
- Sentinel Oncology
- BriaCell Therapeutics
- IMPACT Therapeutics
- Pink Biopharma
- BI 765063
- CBP501
- VER-250840
- SRA737 Sierra Oncology
- PHI-101
- Prexasertib
- SOL 578
- Research program: anticancer therapeutics
- IMP 10
- Research Program: checkpoint kinase inhibitors
Introduction
Executive Summary
Checkpoint kinase inhibitors: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Checkpoint kinase inhibitors – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Checkpoint kinase inhibitors companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Checkpoint kinase inhibitors Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
SRA737: Sierra Oncology
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
CBP501: CanBas
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
VER-250840: Vernalis
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Checkpoint kinase inhibitors Key Companies
Checkpoint kinase inhibitors Key Products
Checkpoint kinase inhibitors- Unmet Needs
Checkpoint kinase inhibitors- Market Drivers and Barriers
Checkpoint kinase inhibitors- Future Perspectives and Conclusion
Checkpoint kinase inhibitors Analyst Views
Checkpoint kinase inhibitors Key Companies
Appendix
Executive Summary
Checkpoint kinase inhibitors: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Checkpoint kinase inhibitors – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Checkpoint kinase inhibitors companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Checkpoint kinase inhibitors Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
SRA737: Sierra Oncology
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
CBP501: CanBas
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
VER-250840: Vernalis
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Checkpoint kinase inhibitors Key Companies
Checkpoint kinase inhibitors Key Products
Checkpoint kinase inhibitors- Unmet Needs
Checkpoint kinase inhibitors- Market Drivers and Barriers
Checkpoint kinase inhibitors- Future Perspectives and Conclusion
Checkpoint kinase inhibitors Analyst Views
Checkpoint kinase inhibitors Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Checkpoint kinase inhibitors
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Checkpoint kinase inhibitors
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Checkpoint kinase inhibitors
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Checkpoint kinase inhibitors
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
